We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Interim Phase II Clinical Data from the OPAL Study Demonstrate Encouraging Single Agent Response Rates for Tosedostat in Elderly Patients with Relapsed Refractory AML

News   Jun 08, 2011

 
New Interim Phase II Clinical Data from the OPAL Study Demonstrate Encouraging Single Agent Response Rates for Tosedostat in Elderly Patients with Relapsed Refractory AML
 
 
 

RELATED ARTICLES

Temperature-stable Tuberculosis Vaccine Enters Clinical Testing

News

Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.

READ MORE

Blindness Prevented in Animal Models of Retinal Degeneration

News

Using a novel patient-specific stem cell-based therapy, blindness was prevented in animal models of geographic atrophy, the advanced 'dry' form of age-related macular degeneration (AMD), which is a leading cause of vision loss among people age 65 and older.

READ MORE

Poo Transplant Shows Promise in Prelim Study for Ulcerative Colitis

News

Anaerobically prepared fecal microbiota transplantation improved remission rates in people with moderately active ulcerative colitis at 8 weeks. Further research is needed to assess longer-term efficacy and safety.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE